Compare Global E Online Ltd (GLBE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Global E Online Ltd trades at $40.37 (market cap $6.75B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Global E Online Ltd is far larger — about 3.2× Recursion Pharmaceuticals Inc's market cap, and Global E Online Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| GLBE | RXRX | |
|---|---|---|
Market Cap | $6.75B | $2.14B |
Volume | 1,468,708 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $6.79 |
52-Week Low | $27.54 | $2.84 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $6.24B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $40.25, up 3.31% today, with a bullish technical signal from moving averages and strong analyst consensus. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth of 39% year-over-year. Recent news includes the appointment of a new Chief Revenue Officer and significant insider selling by executives.
The outlook is positive, supported by strong revenue growth, expanding margins, and a high analyst buy rating. Key risks include elevated valuation multiples, insider selling pressure, and dependence on e-commerce market conditions. The stock offers potential upside to the consensus price target of $48.86.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
